

PRESS RELEASE

First Site in Global Uveal Melanoma Patient Registry Now Open

Eleven centers to capture patient-reported outcomes about rare form of eye cancer

(OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md. & ONTARIO, Canada, 4 March 2019) Immunocore Limited, a leading T cell receptor biotechnology company, and Pulse Inframe Inc. (Pulse), with a platform healthie™ that supports patient registries, data aggregation and analytics, today announce that data collection for the first global patient registry in uveal melanoma (UM) has begun at Columbia University Irving Medical Center in New York. This effort is being co-led by Richard Carvajal, MD, from Columbia University Irving Medical Center and New York-Presbyterian Hospital, US, Joseph Sacco, MD, from the University of Liverpool, UK, and Anthony Joshua, MD, from The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, and the University of New South Wales, Australia. Ten additional centres across the US, UK and Australia are expected to open over the coming year.

Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye and will metastasize in up to 50% of patients. Metastatic UM typically has a poor prognosis and currently has no accepted optimal management or treatment.^{1,2} To help accelerate drug development in UM, Dr. Carvajal began collaborating with other leaders in the field on a patient registry to serve as a resource for academic medical centers and industry partners. Three years later, their vision is now a reality.

“My colleagues and I are committed to the development of a prospective uveal melanoma registry because the need for real-world insight is critical, particularly due to the rarity of this disease,” **commented Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at the Herbert Irving Comprehensive Cancer Center.** “As the registry grows, we look forward to analysing the database and using these data to accelerate the development of new treatments for uveal melanoma.”

The patient registry is designed to provide researchers with a more comprehensive understanding of UM and important benchmarks for future research efforts. Examination of the data will also help to inform critical questions about risk factors, genetics, epidemiology, treatment cost-effectiveness and real-world outcomes, all unlikely to be answered through prospective clinical trials.

“We’re excited that the patient registry is now live and critical information that may help to advance the development of future treatments is now being collected,” **commented Mohammed Dar, MD, Head of Clinical Development and Chief Medical Officer at Immunocore.** “This is a great example of an academia-industry partnership with the goal to generate global data needed to broaden our understanding of uveal melanoma and the people living with this devastating disease. We thank the academic research community for their commitment and help in addressing this important need.”

“There is a real need to have data mapped to global standards to characterise clinical, biomarker and genomic data. Being able to elicit direct feedback from the patient and assess the impact of a disease and treatments on their health-related outcomes provides the holistic view of the patient journey,” **commented Femida Gwadry-Sridhar, RPh, PhD, CEO and Founder, Pulse.** “Using our platform healthie™, we are honoured to support this important global initiative, building on the work we have done in melanoma for the last ten years.”

- Ends -

About the Patient Registry Collaborators

Planning for the UM patient registry began in 2016 with three leaders in the field of UM who continue to guide its implementation today, including:

- Richard Carvajal, MD, Associate Professor of Medicine, Columbia University Vagelos College of Physicians and Surgeons, US
- Joseph Sacco, MD, PhD, Clinical Senior Lecturer at the University of Liverpool and Honorary Consultant in Medical Oncology at Clatterbridge Cancer Centre, UK
- Anthony Joshua, MD, MBBS, PhD, Head, Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, and conjoint Associate Professor with the University of New South Wales, Australia, and Chair, Australasian Ocular Melanoma Alliance

Rich Carvajal receives consulting fees from Immunocore.

About Uveal Melanoma

Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Metastatic uveal melanoma typically has a poor prognosis and has no currently accepted optimal management or treatment.^{1,2} Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases/year in the US).^{3,4,5} Up to 50% of people with uveal melanoma will eventually develop metastatic disease.^{1,2} When the cancer spreads beyond the eye, only approximately half of patients will survive for one year.⁶

About Immunocore

Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered in Oxfordshire, UK, with offices in Conshohocken, PA and Rockville, MD, US. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.

About Pulse Inframe Inc. (Pulse)

Focusing on rare disease and cancer, Pulse is a new style informatics company delivering real-world insights and precision knowledge through dynamic analytics and data visualization to accelerate time-to-value. Pulse aggregates data, including patient reported outcomes, from multiple sources making it available to researchers and relevant stakeholders and offers numerous benefits including dramatically improved collaboration, informing decision making and leading to advances in treatment. Pulse is headquartered in Canada, with offices in the United States. For more information, please visit www.pulseinframe.com.

For more information, please contact:

Immunocore

Louise Stenson, Brand Communications Manager

T: +44 (0) 1235 438600

E: info@immunocore.com

Follow on Twitter and LinkedIn: @Immunocore

¹ Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. *Cancers*. 2019;11(7):971.

² Carvajal, RD, Schwartz, GK, Tezel, T, *et al.*, 2017. Metastatic disease from uveal melanoma: treatment options and future prospects. *British Journal of Ophthalmology*, 101(1), 38-44.

³ Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. *Genes Dev*. 2017;31(8):724-743.

⁴ Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. *Int J Clin Exp Pathol*. 2013;6(7):1230-1244.

⁵ About ocular melanoma. Ocular Melanoma Foundation website. www.ocularmelanoma.org/about-om.htm. Accessed September 2019.

⁶ Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. *Melanoma Res* 2019